CYPH

SEC source: 0001104659-25-030810 · tm2511110-7_4seq1.xml · derivative · entry 3

Granfield Christine · CIK 0001822190 · VP, Head of Reg Affairs/Qual

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each of the January 2022 RSUs represented a contingent right to receive one share of the Company's Common Stock.

F1 · kind: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 15,896 of such shares and the Company withheld on such settlement date the remaining 6,604 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 6,604 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.

F4 · derivative.exercise_date: The January 2022 RSUs became fully vested on January 31, 2025 but settlement thereof was deferred by the Compensation Committee of the Board of Directors of the Company until March 28, 2025 pursuant to, and in accordance with, the terms of the January 2022 RSUs, which terms provide that the Compensation Committee would have the authority to defer the settlement of the January 2022 RSUs to a date later than the vesting date of the January 2022 RSUs in the event that on such vesting date the reporting person were to be subject to, among other things, any limitation or restriction under the Company's insider trading policy that would not permit the reporting person to sell on such vesting date all of the shares of the Company's Common Stock underlying the January 2022 RSUs if the January 2022 RSUs were to be settled on such vesting date.

F5 · derivative.exercise_date: The Compensation Committee of the Board of Directors took action to defer settlement of the January 2022 RSUs so that such settlement would not occur on January 31, 2025, the vesting date thereof. The January 2022 RSUs were settled on March 28, 2025 on a net issue basis as further described on note (2) above.

F6 · derivative.expiration_date: The terms of the January 2022 RSUs provide that the January 2022 RSUs would automatically terminate and be forfeited upon termination of the reporting person's employment or other service relationship with the Company if such termination of employment or service relationship were to occur at any time prior to January 31, 2022, the vesting date of the January 2022 RSUs.

SEC source: 0001104659-25-030810 · tm2511110-7_4seq1.xml · nonDerivative · entry 2

Granfield Christine · CIK 0001822190 · VP, Head of Reg Affairs/Qual

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,896

F1 · kind: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 15,896 of such shares and the Company withheld on such settlement date the remaining 6,604 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 6,604 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.

F2 · balance_after: The share numbers reflected in Tables I and II have been adjusted to take into account a 10-for-1 reverse stock split of the Company's common stock that was effected on June 20, 2023.

SEC source: 0001104659-25-030810 · tm2511110-7_4seq1.xml · nonDerivative · entry 1

Granfield Christine · CIK 0001822190 · VP, Head of Reg Affairs/Qual

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 15,896 of such shares and the Company withheld on such settlement date the remaining 6,604 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 6,604 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.

F3 · price: Each of the January 2022 RSUs represented a contingent right to receive one share of the Company's Common Stock.

F2 · balance_after: The share numbers reflected in Tables I and II have been adjusted to take into account a 10-for-1 reverse stock split of the Company's common stock that was effected on June 20, 2023.

SEC source: 0001104659-25-030804 · tm2511110-1_4seq1.xml · derivative · entry 2

Sirard Cynthia · CIK 0001808408 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each of the January 2022 RSUs represented a contingent right to receive one share of the Company's Common Stock.

F1 · kind: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 such that the Company issued to the reporting person on such settlement date all of the 22,500 shares of the Company's common stock underlying the January 22 RSUs.

F4 · derivative.exercise_date: The January 2022 RSUs became fully vested on January 31, 2025 but settlement thereof was deferred by the Compensation Committee of the Board of Directors of the Company until March 28, 2025 pursuant to, and in accordance with, the terms of the January 2022 RSUs, which terms provide that the Compensation Committee would have the authority to defer the settlement of the January 2022 RSUs to a date later than the vesting date of the January 2022 RSUs in the event that on such vesting date the reporting person were to be subject to, among other things, any limitation or restriction under the Company's insider trading policy that would not permit the reporting person to sell on such vesting date all of the shares of the Company's Common Stock underlying the January 2022 RSUs if the January 2022 RSUs were to be settled on such vesting date.

F5 · derivative.exercise_date: The Compensation Committee of the Board of Directors took action to defer settlement of the January 2022 RSUs so that such settlement would not occur on January 31, 2025, the vesting date thereof. The January 2022 RSUs were settled on March 28, 2025 as further described on note (2) above.

F6 · derivative.expiration_date: The terms of the January 2022 RSUs provide that the January 2022 RSUs would automatically terminate and be forfeited upon termination of the reporting person's employment or other service relationship with the Company if such termination of employment or service relationship were to occur at any time prior to January 31, 2022, the vesting date of the January 2022 RSUs.

SEC source: 0001104659-25-030804 · tm2511110-1_4seq1.xml · nonDerivative · entry 1

Sirard Cynthia · CIK 0001808408 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 such that the Company issued to the reporting person on such settlement date all of the 22,500 shares of the Company's common stock underlying the January 22 RSUs.

F3 · price: Each of the January 2022 RSUs represented a contingent right to receive one share of the Company's Common Stock.

F2 · balance_after: The share numbers reflected in Tables I and II have been adjusted to take into account a 10-for-1 reverse stock split of the Company's common stock that was effected on June 20, 2023.

SEC source: 0001104659-25-030807 · tm2511110-2_4seq1.xml · derivative · entry 2

O'Mahony John Mark · CIK 0001808556 · Chief Manufacturing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each of the January 2022 RSUs represented a contingent right to receive one share of the Company's Common Stock.

F1 · kind: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 such that the Company issued to the reporting person on such settlement date all of the 22,500 shares of the Company's common stock underlying the January 22 RSUs.

F4 · derivative.exercise_date: The January 2022 RSUs became fully vested on January 31, 2025 but settlement thereof was deferred by the Compensation Committee of the Board of Directors of the Company until March 28, 2025 pursuant to, and in accordance with, the terms of the January 2022 RSUs, which terms provide that the Compensation Committee would have the authority to defer the settlement of the January 2022 RSUs to a date later than the vesting date of the January 2022 RSUs in the event that on such vesting date the reporting person were to be subject to, among other things, any limitation or restriction under the Company's insider trading policy that would not permit the reporting person to sell on such vesting date all of the shares of the Company's Common Stock underlying the January 2022 RSUs if the January 2022 RSUs were to be settled on such vesting date.

F5 · derivative.exercise_date: The Compensation Committee of the Board of Directors took action to defer settlement of the January 2022 RSUs so that such settlement would not occur on January 31, 2025, the vesting date thereof. The January 2022 RSUs were settled on March 28, 2025 as further described on note (2) above.

F6 · derivative.expiration_date: The terms of the January 2022 RSUs provide that the January 2022 RSUs would automatically terminate and be forfeited upon termination of the reporting person's employment or other service relationship with the Company if such termination of employment or service relationship were to occur at any time prior to January 31, 2022, the vesting date of the January 2022 RSUs.

SEC source: 0001104659-25-030807 · tm2511110-2_4seq1.xml · nonDerivative · entry 1

O'Mahony John Mark · CIK 0001808556 · Chief Manufacturing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 such that the Company issued to the reporting person on such settlement date all of the 22,500 shares of the Company's common stock underlying the January 22 RSUs.

F3 · price: Each of the January 2022 RSUs represented a contingent right to receive one share of the Company's Common Stock.

F2 · balance_after: The share numbers reflected in Tables I and II have been adjusted to take into account a 10-for-1 reverse stock split of the Company's common stock that was effected on June 20, 2023.

SEC source: 0001104659-25-030811 · tm2511110-4_4seq1.xml · derivative · entry 3

ONSI DOUGLAS E · CIK 0001270185 · Director · CEO,CFO,Pres.,GC,Treas.&Sec.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 32,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each of the January 2022 RSUs represented a contingent right to receive one share of the Company's Common Stock.

F1 · kind: 32,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 such that the Company issued to the reporting person on such settlement date all of the 32,500 shares of the Company's common stock underlying the January 22 RSUs.

F6 · derivative.exercise_date: The January 2022 RSUs became fully vested on January 31, 2025 but settlement thereof was deferred by the Compensation Committee of the Board of Directors of the Company until March 28, 2025 pursuant to, and in accordance with, the terms of the January 2022 RSUs, which terms provide that the Compensation Committee would have the authority to defer the settlement of the January 2022 RSUs to a date later than the vesting date of the January 2022 RSUs in the event that on such vesting date the reporting person were to be subject to, among other things, any limitation or restriction under the Company's insider trading policy that would not permit the reporting person to sell on such vesting date all of the shares of the Company's Common Stock underlying the January 2022 RSUs if the January 2022 RSUs were to be settled on such vesting date.

F7 · derivative.exercise_date: The Compensation Committee of the Board of Directors took action to defer settlement of the January 2022 RSUs so that such settlement would not occur on January 31, 2025, the vesting date thereof. The January 2022 RSUs were settled on March 28, 2025 as further described on note (2) above.

F8 · derivative.expiration_date: The terms of the January 2022 RSUs provide that the January 2022 RSUs would automatically terminate and be forfeited upon termination of the reporting person's employment or other service relationship with the Company if such termination of employment or service relationship were to occur at any time prior to January 31, 2022, the vesting date of the January 2022 RSUs.

SEC source: 0001104659-25-030811 · tm2511110-4_4seq1.xml · nonDerivative · entry 1

ONSI DOUGLAS E · CIK 0001270185 · Director · CEO,CFO,Pres.,GC,Treas.&Sec.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 106,146

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: 32,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 such that the Company issued to the reporting person on such settlement date all of the 32,500 shares of the Company's common stock underlying the January 22 RSUs.

F3 · price: Each of the January 2022 RSUs represented a contingent right to receive one share of the Company's Common Stock.

F2 · balance_after: The share numbers reflected in Tables I and II have been adjusted to take into account a 10-for-1 reverse stock split of the Company's common stock that was effected on June 20, 2023.

SEC source: 0001104659-25-030808 · tm2511110-6_4seq1.xml · derivative · entry 4

LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each of the January 2022 RSUs represented a contingent right to receive one share of the Company's Common Stock.

F1 · kind: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 14,703 of such shares and the Company withheld on such settlement date the remaining 7,797 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 7,797 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.

F6 · derivative.exercise_date: The January 2022 RSUs became fully vested on January 31, 2025 but settlement thereof was deferred by the Compensation Committee of the Board of Directors of the Company until March 28, 2025 pursuant to, and in accordance with, the terms of the January 2022 RSUs, which terms provide that the Compensation Committee would have the authority to defer the settlement of the January 2022 RSUs to a date later than the vesting date of the January 2022 RSUs in the event that on such vesting date the reporting person were to be subject to, among other things, any limitation or restriction under the Company's insider trading policy that would not permit the reporting person to sell on such vesting date all of the shares of the Company's Common Stock underlying the January 2022 RSUs if the January 2022 RSUs were to be settled on such vesting date.

F7 · derivative.exercise_date: The Compensation Committee of the Board of Directors took action to defer settlement of the January 2022 RSUs so that such settlement would not occur on January 31, 2025, the vesting date thereof. The January 2022 RSUs were settled on March 28, 2025 on a net issue basis as further described on note (2) above.

F8 · derivative.expiration_date: The terms of the January 2022 RSUs provide that the January 2022 RSUs would automatically terminate and be forfeited upon termination of the reporting person's employment or other service relationship with the Company if such termination of employment or service relationship were to occur at any time prior to January 31, 2022, the vesting date of the January 2022 RSUs.

SEC source: 0001104659-25-030808 · tm2511110-6_4seq1.xml · nonDerivative · entry 2

LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,789

F1 · kind: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 14,703 of such shares and the Company withheld on such settlement date the remaining 7,797 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 7,797 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.

F2 · balance_after: The share numbers reflected in Tables I and II have been adjusted to take into account a 10-for-1 reverse stock split of the Company's common stock that was effected on June 20, 2023.

SEC source: 0001104659-25-030808 · tm2511110-6_4seq1.xml · nonDerivative · entry 1

LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,586

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 14,703 of such shares and the Company withheld on such settlement date the remaining 7,797 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 7,797 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.

F3 · price: Each of the January 2022 RSUs represented a contingent right to receive one share of the Company's Common Stock.

F2 · balance_after: The share numbers reflected in Tables I and II have been adjusted to take into account a 10-for-1 reverse stock split of the Company's common stock that was effected on June 20, 2023.

SEC source: 0001104659-25-030805 · tm2511110-5_4seq1.xml · derivative · entry 4

Mirabelli Christopher · CIK 0001262326 · Director · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each of the January 2022 RSUs represented a contingent right to receive one share of the Company's Common Stock.

F1 · kind: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 15,828 of such shares and the Company withheld on such settlement date the remaining 6,672 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 6,672 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.

F6 · derivative.exercise_date: The January 2022 RSUs became fully vested on January 31, 2025 but settlement thereof was deferred by the Compensation Committee of the Board of Directors of the Company until March 28, 2025 pursuant to, and in accordance with, the terms of the January 2022 RSUs, which terms provide that the Compensation Committee would have the authority to defer the settlement of the January 2022 RSUs to a date later than the vesting date of the January 2022 RSUs in the event that on such vesting date the reporting person were to be subject to, among other things, any limitation or restriction under the Company's insider trading policy that would not permit the reporting person to sell on such vesting date all of the shares of the Company's Common Stock underlying the January 2022 RSUs if the January 2022 RSUs were to be settled on such vesting date.

F7 · derivative.exercise_date: The Compensation Committee of the Board of Directors took action to defer settlement of the January 2022 RSUs so that such settlement would not occur on January 31, 2025, the vesting date thereof. The January 2022 RSUs were settled on March 28, 2025 on a net issue basis as further described on note (2) above.

F8 · derivative.expiration_date: The terms of the January 2022 RSUs provide that the January 2022 RSUs would automatically terminate and be forfeited upon termination of the reporting person's employment or other service relationship with the Company if such termination of employment or service relationship were to occur at any time prior to January 31, 2022, the vesting date of the January 2022 RSUs.

SEC source: 0001104659-25-030805 · tm2511110-5_4seq1.xml · nonDerivative · entry 2

Mirabelli Christopher · CIK 0001262326 · Director · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,914

F1 · kind: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 15,828 of such shares and the Company withheld on such settlement date the remaining 6,672 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 6,672 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.

F2 · balance_after: The share numbers reflected in Tables I and II have been adjusted to take into account a 10-for-1 reverse stock split of the Company's common stock that was effected on June 20, 2023.

SEC source: 0001104659-25-030805 · tm2511110-5_4seq1.xml · nonDerivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,586

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 15,828 of such shares and the Company withheld on such settlement date the remaining 6,672 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 6,672 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.

F3 · price: Each of the January 2022 RSUs represented a contingent right to receive one share of the Company's Common Stock.

F2 · balance_after: The share numbers reflected in Tables I and II have been adjusted to take into account a 10-for-1 reverse stock split of the Company's common stock that was effected on June 20, 2023.

SEC source: 0001104659-25-030809 · tm2511110-3_4seq1.xml · derivative · entry 3

Baum Jason · CIK 0001970907 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each of the January 2022 RSUs represented a contingent right to receive one share of the Company's Common Stock.

F1 · kind: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 15,896 of such shares and the Company withheld on such settlement date the remaining 6,604 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 6,604 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.

F4 · derivative.exercise_date: The January 2022 RSUs became fully vested on January 31, 2025 but settlement thereof was deferred by the Compensation Committee of the Board of Directors of the Company until March 28, 2025 pursuant to, and in accordance with, the terms of the January 2022 RSUs, which terms provide that the Compensation Committee would have the authority to defer the settlement of the January 2022 RSUs to a date later than the vesting date of the January 2022 RSUs in the event that on such vesting date the reporting person were to be subject to, among other things, any limitation or restriction under the Company's insider trading policy that would not permit the reporting person to sell on such vesting date all of the shares of the Company's Common Stock underlying the January 2022 RSUs if the January 2022 RSUs were to be settled on such vesting date.

F5 · derivative.exercise_date: The Compensation Committee of the Board of Directors took action to defer settlement of the January 2022 RSUs so that such settlement would not occur on January 31, 2025, the vesting date thereof. The January 2022 RSUs were settled on March 28, 2025 on a net issue basis as further described on note (2) above.

F6 · derivative.expiration_date: The terms of the January 2022 RSUs provide that the January 2022 RSUs would automatically terminate and be forfeited upon termination of the reporting person's employment or other service relationship with the Company if such termination of employment or service relationship were to occur at any time prior to January 31, 2022, the vesting date of the January 2022 RSUs.

SEC source: 0001104659-25-030809 · tm2511110-3_4seq1.xml · nonDerivative · entry 2

Baum Jason · CIK 0001970907 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,896

F1 · kind: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 15,896 of such shares and the Company withheld on such settlement date the remaining 6,604 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 6,604 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.

F2 · balance_after: The share numbers reflected in Tables I and II have been adjusted to take into account a 10-for-1 reverse stock split of the Company's common stock that was effected on June 20, 2023.

SEC source: 0001104659-25-030809 · tm2511110-3_4seq1.xml · nonDerivative · entry 1

Baum Jason · CIK 0001970907 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 15,896 of such shares and the Company withheld on such settlement date the remaining 6,604 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 6,604 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person.

F3 · price: Each of the January 2022 RSUs represented a contingent right to receive one share of the Company's Common Stock.

F2 · balance_after: The share numbers reflected in Tables I and II have been adjusted to take into account a 10-for-1 reverse stock split of the Company's common stock that was effected on June 20, 2023.

SEC source: 0001104659-24-119795 · tm2428586-4_4seq1.xml · derivative · entry 3

CAVANAUGH JAMES H · CIK 0001013473 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, $0.001 par value per share · 213 shares

Expires 2024-11-14

F1 · kind: On November 13, 2024, James Cavanaugh exercised a warrant to purchase 213 shares of the Issuer's common stock at an exercise price of $2.82 per share.

SEC source: 0001104659-24-119795 · tm2428586-4_4seq1.xml · nonDerivative · entry 1

CAVANAUGH JAMES H · CIK 0001013473 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 213

F1 · kind: On November 13, 2024, James Cavanaugh exercised a warrant to purchase 213 shares of the Issuer's common stock at an exercise price of $2.82 per share.

SEC source: 0001104659-24-119794 · tm2428586-3_4seq1.xml · derivative · entry 3

ONSI DOUGLAS E · CIK 0001270185 · Director · CEO,CFO,Pres.,GC,Treas.&Sec.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock, $0.001 par value per share · 2,136 shares

Expires 2024-11-14

F1 · kind: On November 13, 2024, Nine Capital Partners, LLC ("Nine Capital Partners") exercised a warrant to purchase 2,136 shares of the Issuer's common stock at an exercise price of $2.82 per share. The reporting person is a managing member of Nine Capital Partners and may be deemed to have had beneficial ownership of such warrant exercised by Nine Capital Partners and to have beneficial ownership of the 2,136 shares of Common Stock purchased by Nine Capital Partners upon exercise of such warrant. The reporting person disclaims beneficial ownership of such warrant and of such shares of Common Stock, except to the extent of the reporting person's proportionate pecuniary interest in such warrant and such shares of Common Stock.

F1 · ownership.nature: On November 13, 2024, Nine Capital Partners, LLC ("Nine Capital Partners") exercised a warrant to purchase 2,136 shares of the Issuer's common stock at an exercise price of $2.82 per share. The reporting person is a managing member of Nine Capital Partners and may be deemed to have had beneficial ownership of such warrant exercised by Nine Capital Partners and to have beneficial ownership of the 2,136 shares of Common Stock purchased by Nine Capital Partners upon exercise of such warrant. The reporting person disclaims beneficial ownership of such warrant and of such shares of Common Stock, except to the extent of the reporting person's proportionate pecuniary interest in such warrant and such shares of Common Stock.

SEC source: 0001104659-24-119794 · tm2428586-3_4seq1.xml · nonDerivative · entry 1

ONSI DOUGLAS E · CIK 0001270185 · Director · CEO,CFO,Pres.,GC,Treas.&Sec.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 678,456

F1 · kind: On November 13, 2024, Nine Capital Partners, LLC ("Nine Capital Partners") exercised a warrant to purchase 2,136 shares of the Issuer's common stock at an exercise price of $2.82 per share. The reporting person is a managing member of Nine Capital Partners and may be deemed to have had beneficial ownership of such warrant exercised by Nine Capital Partners and to have beneficial ownership of the 2,136 shares of Common Stock purchased by Nine Capital Partners upon exercise of such warrant. The reporting person disclaims beneficial ownership of such warrant and of such shares of Common Stock, except to the extent of the reporting person's proportionate pecuniary interest in such warrant and such shares of Common Stock.

F2 · balance_after: Includes (i) 2,136 shares of Common Stock held by Nine Capital Partners, (ii) 414,480 shares of Common Stock held by HealthCare Ventures IX, L.P. ("HCV IX"), and (iii) 261,840 shares of Common Stock held by the HCV VIII Trust ("HCV Trust"). See footnote (1) above for an explanation of the reporting person's beneficial ownership of the 2,136 shares of Common Stock held by Nine Capital Partners. The reporting person is a Managing Director of HCPIX LLC, which is the General Partner of HealthCare Partners IX, which is the General Partner of HCV IX and may be deemed to have beneficial ownership of the 414,480 shares of Common Stock held by HCV IX. The reporting person is a beneficiary of the HCV Trust and may be deemed to have beneficial ownership of the 261,840 shares of Common Stock held by the HCV Trust.

F3 · balance_after: The reporting person disclaims beneficial ownership of such shares of Common Stock held by each of Nine Capital Partners, HCV IX, and the HCV Trust, except to the extent of the reporting person's proportionate pecuniary interest in such shares of Common Stock.

F1 · ownership.nature: On November 13, 2024, Nine Capital Partners, LLC ("Nine Capital Partners") exercised a warrant to purchase 2,136 shares of the Issuer's common stock at an exercise price of $2.82 per share. The reporting person is a managing member of Nine Capital Partners and may be deemed to have had beneficial ownership of such warrant exercised by Nine Capital Partners and to have beneficial ownership of the 2,136 shares of Common Stock purchased by Nine Capital Partners upon exercise of such warrant. The reporting person disclaims beneficial ownership of such warrant and of such shares of Common Stock, except to the extent of the reporting person's proportionate pecuniary interest in such warrant and such shares of Common Stock.

F2 · ownership.nature: Includes (i) 2,136 shares of Common Stock held by Nine Capital Partners, (ii) 414,480 shares of Common Stock held by HealthCare Ventures IX, L.P. ("HCV IX"), and (iii) 261,840 shares of Common Stock held by the HCV VIII Trust ("HCV Trust"). See footnote (1) above for an explanation of the reporting person's beneficial ownership of the 2,136 shares of Common Stock held by Nine Capital Partners. The reporting person is a Managing Director of HCPIX LLC, which is the General Partner of HealthCare Partners IX, which is the General Partner of HCV IX and may be deemed to have beneficial ownership of the 414,480 shares of Common Stock held by HCV IX. The reporting person is a beneficiary of the HCV Trust and may be deemed to have beneficial ownership of the 261,840 shares of Common Stock held by the HCV Trust.

F3 · ownership.nature: The reporting person disclaims beneficial ownership of such shares of Common Stock held by each of Nine Capital Partners, HCV IX, and the HCV Trust, except to the extent of the reporting person's proportionate pecuniary interest in such shares of Common Stock.

SEC source: 0001104659-24-119793 · tm2428586-2_4seq1.xml · derivative · entry 3

LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock, $0.001 par value per share · 2,136 shares

Expires 2024-11-14

F1 · kind: On November 13, 2024, Nine Capital Partners, LLC ("Nine Capital Partners") exercised a warrant to purchase 2,136 shares of the Issuer's common stock at an exercise price of $2.82 per share. The reporting person is a managing member of Nine Capital Partners and may be deemed to have had beneficial ownership of such warrant exercised by Nine Capital Partners and to have beneficial ownership of the 2,136 shares of Common Stock purchased by Nine Capital Partners upon exercise of such warrant. The reporting person disclaims beneficial ownership of such warrant and of such shares of Common Stock, except to the extent of the reporting person's proportionate pecuniary interest in such warrant and such shares of Common Stock.

F1 · ownership.nature: On November 13, 2024, Nine Capital Partners, LLC ("Nine Capital Partners") exercised a warrant to purchase 2,136 shares of the Issuer's common stock at an exercise price of $2.82 per share. The reporting person is a managing member of Nine Capital Partners and may be deemed to have had beneficial ownership of such warrant exercised by Nine Capital Partners and to have beneficial ownership of the 2,136 shares of Common Stock purchased by Nine Capital Partners upon exercise of such warrant. The reporting person disclaims beneficial ownership of such warrant and of such shares of Common Stock, except to the extent of the reporting person's proportionate pecuniary interest in such warrant and such shares of Common Stock.

SEC source: 0001104659-24-119793 · tm2428586-2_4seq1.xml · nonDerivative · entry 1

LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 678,456

F1 · kind: On November 13, 2024, Nine Capital Partners, LLC ("Nine Capital Partners") exercised a warrant to purchase 2,136 shares of the Issuer's common stock at an exercise price of $2.82 per share. The reporting person is a managing member of Nine Capital Partners and may be deemed to have had beneficial ownership of such warrant exercised by Nine Capital Partners and to have beneficial ownership of the 2,136 shares of Common Stock purchased by Nine Capital Partners upon exercise of such warrant. The reporting person disclaims beneficial ownership of such warrant and of such shares of Common Stock, except to the extent of the reporting person's proportionate pecuniary interest in such warrant and such shares of Common Stock.

F2 · balance_after: Includes (i) 2,136 shares of Common Stock held by Nine Capital Partners, (ii) 414,480 shares of Common Stock held by HealthCare Ventures IX, L.P. ("HCV IX"), and (iii) 261,840 shares of Common Stock held by the HCV VIII Trust ("HCV Trust"). See footnote (1) above for an explanation of the reporting person's beneficial ownership of the 2,136 shares of Common Stock held by Nine Capital Partners. The reporting person is a Managing Director of HCPIX LLC, which is the General Partner of HealthCare Partners IX, which is the General Partner of HCV IX and may be deemed to have beneficial ownership of the 414,480 shares of Common Stock held by HCV IX. The reporting person is the manager and a beneficiary of the HCV Trust and may be deemed to have beneficial ownership of the 261,840 shares of Common Stock held by the HCV Trust.

F3 · balance_after: The reporting person disclaims beneficial ownership of such shares of Common Stock held by each of Nine Capital Partners, HCV IX, and the HCV Trust, except to the extent of the reporting person's proportionate pecuniary interest in such shares of Common Stock.

F1 · ownership.nature: On November 13, 2024, Nine Capital Partners, LLC ("Nine Capital Partners") exercised a warrant to purchase 2,136 shares of the Issuer's common stock at an exercise price of $2.82 per share. The reporting person is a managing member of Nine Capital Partners and may be deemed to have had beneficial ownership of such warrant exercised by Nine Capital Partners and to have beneficial ownership of the 2,136 shares of Common Stock purchased by Nine Capital Partners upon exercise of such warrant. The reporting person disclaims beneficial ownership of such warrant and of such shares of Common Stock, except to the extent of the reporting person's proportionate pecuniary interest in such warrant and such shares of Common Stock.

F2 · ownership.nature: Includes (i) 2,136 shares of Common Stock held by Nine Capital Partners, (ii) 414,480 shares of Common Stock held by HealthCare Ventures IX, L.P. ("HCV IX"), and (iii) 261,840 shares of Common Stock held by the HCV VIII Trust ("HCV Trust"). See footnote (1) above for an explanation of the reporting person's beneficial ownership of the 2,136 shares of Common Stock held by Nine Capital Partners. The reporting person is a Managing Director of HCPIX LLC, which is the General Partner of HealthCare Partners IX, which is the General Partner of HCV IX and may be deemed to have beneficial ownership of the 414,480 shares of Common Stock held by HCV IX. The reporting person is the manager and a beneficiary of the HCV Trust and may be deemed to have beneficial ownership of the 261,840 shares of Common Stock held by the HCV Trust.

F3 · ownership.nature: The reporting person disclaims beneficial ownership of such shares of Common Stock held by each of Nine Capital Partners, HCV IX, and the HCV Trust, except to the extent of the reporting person's proportionate pecuniary interest in such shares of Common Stock.

SEC source: 0001104659-24-119791 · tm2428586-1_4seq1.xml · derivative · entry 3

Mirabelli Christopher · CIK 0001262326 · Director · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock, $0.001 par value per share · 2,136 shares

Expires 2024-11-14

F1 · kind: On November 13, 2024, Nine Capital Partners, LLC ("Nine Capital Partners") exercised a warrant to purchase 2,136 shares of the Issuer's common stock at an exercise price of $2.82 per share. The reporting person is a managing member of Nine Capital Partners and may be deemed to have had beneficial ownership of such warrant exercised by Nine Capital Partners and to have beneficial ownership of the 2,136 shares of Common Stock purchased by Nine Capital Partners upon exercise of such warrant. The reporting person disclaims beneficial ownership of such warrant and of such shares of Common Stock, except to the extent of the reporting person's proportionate pecuniary interest in such warrant and such shares of Common Stock.

F1 · ownership.nature: On November 13, 2024, Nine Capital Partners, LLC ("Nine Capital Partners") exercised a warrant to purchase 2,136 shares of the Issuer's common stock at an exercise price of $2.82 per share. The reporting person is a managing member of Nine Capital Partners and may be deemed to have had beneficial ownership of such warrant exercised by Nine Capital Partners and to have beneficial ownership of the 2,136 shares of Common Stock purchased by Nine Capital Partners upon exercise of such warrant. The reporting person disclaims beneficial ownership of such warrant and of such shares of Common Stock, except to the extent of the reporting person's proportionate pecuniary interest in such warrant and such shares of Common Stock.

SEC source: 0001104659-24-119791 · tm2428586-1_4seq1.xml · nonDerivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 678,456

F1 · kind: On November 13, 2024, Nine Capital Partners, LLC ("Nine Capital Partners") exercised a warrant to purchase 2,136 shares of the Issuer's common stock at an exercise price of $2.82 per share. The reporting person is a managing member of Nine Capital Partners and may be deemed to have had beneficial ownership of such warrant exercised by Nine Capital Partners and to have beneficial ownership of the 2,136 shares of Common Stock purchased by Nine Capital Partners upon exercise of such warrant. The reporting person disclaims beneficial ownership of such warrant and of such shares of Common Stock, except to the extent of the reporting person's proportionate pecuniary interest in such warrant and such shares of Common Stock.

F2 · balance_after: Includes (i) 2,136 shares of Common Stock held by Nine Capital Partners, (ii) 414,480 shares of Common Stock held by HealthCare Ventures IX, L.P. ("HCV IX"), and (iii) 261,840 shares of Common Stock held by the HCV VIII Trust ("HCV Trust"). See footnote (1) above for an explanation of the reporting person's beneficial ownership of the 2,136 shares of Common Stock held by Nine Capital Partners. The reporting person is a Managing Director of HCPIX LLC, which is the General Partner of HealthCare Partners IX, which is the General Partner of HCV IX and may be deemed to have beneficial ownership of the 414,480 shares of Common Stock held by HCV IX. The reporting person is a beneficiary of the HCV Trust and may be deemed to have beneficial ownership of the 261,840 shares of Common Stock held by the HCV Trust.

F3 · balance_after: The reporting person disclaims beneficial ownership of such shares of Common Stock held by each of Nine Capital Partners, HCV IX, and the HCV Trust, except to the extent of the reporting person's proportionate pecuniary interest in such shares of Common Stock.

F1 · ownership.nature: On November 13, 2024, Nine Capital Partners, LLC ("Nine Capital Partners") exercised a warrant to purchase 2,136 shares of the Issuer's common stock at an exercise price of $2.82 per share. The reporting person is a managing member of Nine Capital Partners and may be deemed to have had beneficial ownership of such warrant exercised by Nine Capital Partners and to have beneficial ownership of the 2,136 shares of Common Stock purchased by Nine Capital Partners upon exercise of such warrant. The reporting person disclaims beneficial ownership of such warrant and of such shares of Common Stock, except to the extent of the reporting person's proportionate pecuniary interest in such warrant and such shares of Common Stock.

F2 · ownership.nature: Includes (i) 2,136 shares of Common Stock held by Nine Capital Partners, (ii) 414,480 shares of Common Stock held by HealthCare Ventures IX, L.P. ("HCV IX"), and (iii) 261,840 shares of Common Stock held by the HCV VIII Trust ("HCV Trust"). See footnote (1) above for an explanation of the reporting person's beneficial ownership of the 2,136 shares of Common Stock held by Nine Capital Partners. The reporting person is a Managing Director of HCPIX LLC, which is the General Partner of HealthCare Partners IX, which is the General Partner of HCV IX and may be deemed to have beneficial ownership of the 414,480 shares of Common Stock held by HCV IX. The reporting person is a beneficiary of the HCV Trust and may be deemed to have beneficial ownership of the 261,840 shares of Common Stock held by the HCV Trust.

F3 · ownership.nature: The reporting person disclaims beneficial ownership of such shares of Common Stock held by each of Nine Capital Partners, HCV IX, and the HCV Trust, except to the extent of the reporting person's proportionate pecuniary interest in such shares of Common Stock.

SEC source: 0001104659-24-106350 · tm2425653-15_4seq1.xml · derivative · entry 1

Granfield Christine · CIK 0001822190 · VP, Head of Reg Affairs/Qual

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2034-10-02

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on the one month anniversary of October 2, 2024.

SEC source: 0001104659-24-106332 · tm2425653-2_4seq1.xml · derivative · entry 1

CAVANAUGH JAMES H · CIK 0001013473 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2034-10-02

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of December 31, 2024, March 31, 2025, June 30, 2025, and September 30, 2025 for so long as the reporting person continues to be a director, consultant or service provider of the Company.

SEC source: 0001104659-24-106347 · tm2425653-14_4seq1.xml · derivative · entry 1

Sirard Cynthia · CIK 0001808408 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2034-10-02

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on the one month anniversary of October 2, 2024.

SEC source: 0001104659-24-106336 · tm2425653-10_4seq1.xml · derivative · entry 1

O'Mahony John Mark · CIK 0001808556 · Chief Manufacturing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2034-10-02

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on the one month anniversary of October 2, 2024.

SEC source: 0001104659-24-106337 · tm2425653-5_4seq1.xml · derivative · entry 1

LI WILLIAM · CIK 0001273806 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2034-10-02

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of December 31, 2024, March 31, 2025, June 30, 2025, and September 30, 2025 for so long as the reporting person continues to be a director, consultant or service provider of the Company.

SEC source: 0001104659-24-106339 · tm2425653-11_4seq1.xml · derivative · entry 1

ONSI DOUGLAS E · CIK 0001270185 · Director · CEO,CFO,Pres.,GC,Treas.,&Sec.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 170,000

Underlying: Common Stock · 170,000 shares

Expires 2034-10-02

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on the one month anniversary of October 2, 2024.

SEC source: 0001104659-24-106335 · tm2425653-4_4seq1.xml · derivative · entry 1

LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2034-10-02

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on the one month anniversary of October 2, 2024.

SEC source: 0001104659-24-106331 · tm2425653-9_4seq1.xml · derivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2034-10-02

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on the one month anniversary of October 2, 2024.

SEC source: 0001104659-24-106338 · tm2425653-6_4seq1.xml · derivative · entry 1

LOSCALZO JOSEPH · CIK 0001276128 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2034-10-02

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of December 31, 2024, March 31, 2025, June 30, 2025, and September 30, 2025 for so long as the reporting person continues to be a director, consultant or service provider of the Company.

SEC source: 0001104659-24-106329 · tm2425653-8_4seq1.xml · derivative · entry 1

Mashiach Nissim · CIK 0001357777 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2034-10-02

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of December 31, 2024, March 31, 2025, June 30, 2025, and September 30, 2025 for so long as the reporting person continues to be a director, consultant or service provider of the Company.

SEC source: 0001104659-24-106345 · tm2425653-13_4seq1.xml · derivative · entry 1

Schilsky Richard · CIK 0001945662 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2034-10-02

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of December 31, 2024, March 31, 2025, June 30, 2025, and September 30, 2025 for so long as the reporting person continues to be a director, consultant or service provider of the Company.

SEC source: 0001104659-24-106343 · tm2425653-12_4seq1.xml · derivative · entry 1

Richard Christian M · CIK 0001645967 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2034-10-02

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of December 31, 2024, March 31, 2025, June 30, 2025, and September 30, 2025 for so long as the reporting person continues to be a director, consultant or service provider of the Company.

SEC source: 0001104659-24-106340 · tm2425653-7_4seq1.xml · derivative · entry 1

Martin Patricia A. · CIK 0001916764 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2034-10-02

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of December 31, 2024, March 31, 2025, June 30, 2025, and September 30, 2025 and for so long as the reporting person continues to be a director, consultant or service provider of the Company.

SEC source: 0001104659-24-106333 · tm2425653-3_4seq1.xml · derivative · entry 1

Dietz Thomas John · CIK 0001574218 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2034-10-02

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of December 31, 2024, March 31, 2025, June 30, 2025, and September 30, 2025 for so long as the reporting person continues to be a director, consultant or service provider of the Company.

SEC source: 0001104659-24-106330 · tm2425653-1_4seq1.xml · derivative · entry 1

Baum Jason · CIK 0001970907 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2034-10-02

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on the one month anniversary of October 2, 2024.

SEC source: 0001104659-24-009028 · tm244775-7_4seq1.xml · derivative · entry 1

Granfield Christine · CIK 0001822190 · VP, Head of Reg Affairs/Qual

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2034-01-29

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on the one month anniversary of January 29, 2024.

SEC source: 0001104659-24-009016 · tm244775-9_4seq1.xml · derivative · entry 1

CAVANAUGH JAMES H · CIK 0001013473 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2034-01-29

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024 for so long as the reporting person continues to be a director, consultant or service provider of the Company.

SEC source: 0001104659-24-009024 · tm244775-4_4seq1.xml · derivative · entry 1

Sirard Cynthia · CIK 0001808408 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2034-01-29

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on the one month anniversary of January 29, 2024.

SEC source: 0001104659-24-009025 · tm244775-5_4seq1.xml · derivative · entry 1

O'Mahony John Mark · CIK 0001808556 · Chief Manufacturing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2034-01-29

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on the one month anniversary of January 29, 2024.

SEC source: 0001104659-24-009017 · tm244775-10_4seq1.xml · derivative · entry 1

LI WILLIAM · CIK 0001273806 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2034-01-29

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024 for so long as the reporting person continues to be a director, consultant or service provider of the Company.

SEC source: 0001104659-24-009018 · tm244775-1_4seq1.xml · derivative · entry 1

ONSI DOUGLAS E · CIK 0001270185 · Director · CEO,CFO,Pres.,GC,Treas.,&Sec.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 170,000

Underlying: Common Stock · 170,000 shares

Expires 2034-01-29

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on the one month anniversary of January 29, 2024.

SEC source: 0001104659-24-009022 · tm244775-3_4seq1.xml · derivative · entry 1

LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2034-01-29

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on the one month anniversary of January 29, 2024.

SEC source: 0001104659-24-009020 · tm244775-2_4seq1.xml · derivative · entry 1

Mirabelli Christopher · CIK 0001262326 · Director · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2034-01-29

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on the one month anniversary of January 29, 2024.

SEC source: 0001104659-24-009021 · tm244775-11_4seq1.xml · derivative · entry 1

LOSCALZO JOSEPH · CIK 0001276128 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2034-01-29

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024 for so long as the reporting person continues to be a director, consultant or service provider of the Company.